Achmea Investment Management B.V. Increases Holdings in Pfizer Inc. (NYSE:PFE)

Achmea Investment Management B.V. grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 194.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 311,902 shares of the biopharmaceutical company's stock after purchasing an additional 205,886 shares during the period. Achmea Investment Management B.V.'s holdings in Pfizer were worth $7,904,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the 4th quarter worth $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer in the 4th quarter worth $27,000. Gould Capital LLC increased its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the 4th quarter worth $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer in the 4th quarter worth $30,000. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Stock Performance

NYSE:PFE traded down $0.04 during mid-day trading on Friday, hitting $24.20. 39,502,107 shares of the company traded hands, compared to its average volume of 41,339,880. The stock's fifty day moving average price is $23.46 and its 200-day moving average price is $24.85. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a market cap of $137.56 billion, a price-to-earnings ratio of 17.53, a price-to-earnings-growth ratio of 0.88 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the company posted $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.11%. Pfizer's payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.